Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Trial of Nelfinavir and Bortezomib in Advanced Hematologic Malignancies.

Next Previous
Search
Trial Profile

Phase I Trial of Nelfinavir and Bortezomib in Advanced Hematologic Malignancies.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Nelfinavir (Primary)
  • Indications Acute myeloid leukaemia; Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Hodgkin's disease; Large granular lymphocytic leukaemia; Lymphoproliferative disorders; Mantle-cell lymphoma; Multiple myeloma; Mycosis fungoides; Peripheral T-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Sezary syndrome; T-cell lymphoma; T-cell prolymphocytic leukaemia
  • Focus Adverse reactions

    • Most Recent Events

    • 10 Dec 2013 Planned end date changed from 1 Mar 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
    • 10 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 26 Apr 2012 Planned number of patients changed from 18 to 24 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top